Table 2.

Susceptibilities of 336 clinical isolates of P. aeruginosa to 10 fluoroquinolones

DrugMIC (μg/ml) for strains with the following GyrA alterationsa (type of change):
PAO1Wild type (n = 265)bThr-83→Ile (PU→NH) (n = 63)Ala-84→Pro (NH→NH) (n = 1)Asp-87→Gly (−1c→PU) (n = 1)Asp-87→Asn (−1→PU) (n = 2)Asp-87→Tyrd (−1→PU) (n = 1)Gln-106→Leu (PU→NH) (n = 1)Ala-67, Asp-87→Ser, Gly (NH, −1→PU, PU) (n = 1)Thr-83, Asp-87→Ile, Gly (PU, −1→NH, PU) (n = 1)
Range50%90%Range50%90%
Norfloxacin0.390.20–1000.783.131.56–4001002002512.51.56, 12.512.52512.5200
Ofloxacin0.780.39–1001.566.253.13–800502002512.53.13, 2512.52512.5200
Enoxacin0.780.20–2001.566.253.13–>400100>40025253.13, 25502525200
Ciprofloxacin0.100.025–500.200.780.39–40025506.253.130.78, 3.136.253.133.1350
Tosufloxacin0.200.05–>250.391.560.10–>25>25>256.256.250.78, 1.563.131.566.25>25
Lomefloxacin0.780.39–2001.566.250.78–80020040050256.25, 50255025400
Fleroxacin0.780.20–2001.566.253.13–>1,6001004002512.53.13, 25252512.5400
Sparfloxacin0.780.20–2001.563.131.56–>1,60010020012.512.51.56, 12.512.5256.25200
Gatifloxacin0.780.20–501.563.131.56–2005010012.56.251.56, 6.256.2512.56.2550
CS-9400.390.10–500.783.131.56–800501006.253.130.78, 12.53.1312.56.25100
  • a Silent mutation is neglected.

  • b n indicates number of strains.

  • c −1, negatively charged.

  • d Strain Y4492.